Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML0331

Sigma-Aldrich

Prasugrel

≥98% (HPLC)

Synonym(e):

5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate, CS 747, CS-747, Effient, Efient, LY640315

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

10 MG
CHF 103.00
50 MG
CHF 398.00

CHF 103.00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
10 MG
CHF 103.00
50 MG
CHF 398.00

About This Item

Empirische Formel (Hill-System):
C20H20FNO3S
CAS-Nummer:
150322-43-3
Molekulargewicht:
373.44
MDL-Nummer:
MFCD09954140
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825336
NACRES:
NA.77

CHF 103.00

Check Cart for Availability
Bulk-Bestellung anfordern

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: >5 mg/mL (warmed at 60 °C)

Lagertemp.

2-8°C

SMILES String

CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C3CC3)c4ccccc4F

InChI

1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3

InChIKey

DTGLZDAWLRGWQN-UHFFFAOYSA-N

Angaben zum Gen

human ... P2RY12(64805)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors.
Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors. Prasugrel interacts in an irreversible manner with the residues Cys97 and Cys175 of the human P2Y12-receptor.
Prasugrel is a thienopyridine prodrug and is considered to be more potent than clopidogrel. It shows a faster generation and also reduces thrombotic events.[1] Prasugrel is less dependent on the CYP (cytochrome P450) enzymes for its conversion to active metabolite.[2]

Leistungsmerkmale und Vorteile

This compound is featured on the P2 Receptors: P2Y G-Protein Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000174550
0000174549
052M4702V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 4

1 of 4

Ticlopidin -hydrochlorid analytical standard, for drug analysis

Supelco

T6654

Ticlopidin -hydrochlorid

Irinotecan -hydrochlorid topoisomerase inhibitor

Sigma-Aldrich

I1406

Irinotecan -hydrochlorid

Salicylsäure ACS reagent, ≥99.0%

Sigma-Aldrich

247588

Salicylsäure

Acetylsalicylsäure ≥99.0%

Sigma-Aldrich

A5376

Acetylsalicylsäure

Matti K Itkonen et al.
Clinical pharmacology and therapeutics, 104(3), 495-504 (2017-11-25)
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we investigated the effects of two widely used P2Y12 inhibitors on montelukast pharmacokinetics. Clopidogrel (300 mg on day
Antonio Tello-Montoliu et al.
Platelets, 27(8), 777-783 (2016-06-04)
Everolimus-eluting bioabsorbable scaffolds (BVSs) have exhibited similar long-term clinical outcomes compared to its everolimus-eluting metallic counterparts. However, reports from earlier studies have shown a signal for an increased rate of stent thrombosis. The aim of the current investigation is to
Shigeru Saito et al.
Circulation journal : official journal of the Japanese Circulation Society, 78(7), 1684-1692 (2014-04-25)
Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the efficacy and safety of prasugrel at loading/maintenance doses of 20/3.75 mg. Japanese patients (n=1,363) with
Juan F Iglesias et al.
Lancet (London, England), 394(10205), 1243-1253 (2019-09-07)
Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents.
Jeffrey A Bakal et al.
European heart journal, 36(6), 385-92a-385-92a (2014-07-12)
Several methods provide new insights into understanding clinical trial composite endpoints, using both conventional and novel methods. The TRILOGY ACS trial is used as a contemporary example to prospectively compare these methods side by side. The traditional time-to-first-event, Andersen-Gill recurrent
Alle zugehörigen Dokumente anzeigen

Artikel

P2 Receptors: P2Y G-Protein Family Overview

Surface receptors for extracellular nucleotides are called P2 receptors. Learn more about P2Y G protein-coupled receptors, GPCRs, and ionotropic P2 receptors (P2X ligand-gated ion channels, LGICs).

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.